Skip to content
    Apple Tree Partners logo

    Apple Tree Partners

    New York, New York, United StatesFounded 1999
    www.appletreepartners.comLinkedIn
    Biotech & Life SciencesHealthcare

    Apple Tree Partners (ATP) is a life sciences venture capital firm founded in 1999 that creates and builds transformative biotechnology and therapeutics companies. ATP invests from pre-IP ideas and asset spinouts through seed stage, clinical development, IPO, and beyond.

    48% of their portfolio is in Biotech & Life Sciences. They made 1 investments in the last 12 months. Their most common stage is series-a (43% of deals). Average disclosed round size is $46.4M (across 22 rounds with reported amounts).

    Find people at Apple Tree Partners on Goldilocks AI

    Portfolio

    18

    Fund Size

    $2.5B

    Top Stage

    Series A

    Last 12 Mo

    0

    Team

    SH

    Seth Harrison

    founder and managing partner of ATP (Apple Tree Partners)

    SL

    Seth L. Harrison, MD

    founder and managing partner

    AB

    Anna Batarina

    partner at Apple Tree Partners (ATP)

    AB

    Anna Batarina, CFA

    partner

    JA

    Joseph A. Yanchik III

    venture partner

    JY

    Joseph Yanchik

    venture partner at ATP

    MM

    Mark Mitchnick, MD

    venture partner

    PD

    Paul Da Silva Jardine

    venture partner at ATP

    PD

    Paul Da Silva Jardine, PhD

    venture partner

    PE

    Paul Eisenberg

    chief medical officer and venture partner at ATP

    PE

    Paul Eisenberg, MD

    chief medical officer and venture partner

    SL

    Spiros Liras

    venture partner at ATP

    Portfolio Breakdown

    Stage Distribution

    Sector Distribution

    Investment Activity

    DealsAvg Round Size

    Portfolio

    23 investments
    CompanyRoundAmountDate
    Galvanize Therapeutics logoGalvanize TherapeuticsSeries C$100MSep 2025
    Ascidian Therapeutics logoAscidian TherapeuticsSeries A$40MNov 2023
    Galvanize Therapeutics logoGalvanize TherapeuticsSeries B$100MSep 2022
    AAdendra TherapeuticsSeries A—Dec 2021
    Aulos Bioscience logoAulos BioscienceSeries A$20MJan 2021
    IIntergalactic TherapeuticsSeries A$75MJan 2021
    Nereid Therapeutics logoNereid TherapeuticsSeries A$50MJan 2020
    Chinook Therapeutics logoChinook TherapeuticsSeries A$65MAug 2019
    Akero Therapeutics logoAkero TherapeuticsSeries B$70MDec 2018
    CCorvidiaSeries B$60MApr 2018
    Stoke Therapeutics logoStoke TherapeuticsSeries B$90MJan 2018
    SSyntimmuneSeries B$50MJan 2017
    ROX Medical logoROX MedicalSeries E$40MSep 2016
    CCorvidia TherapeuticsSeries A$26MFeb 2016
    CCorvidiaSeries A$26MJan 2016
    SSyntimmuneSeries A$8MJan 2016
    VVytronUSSeries B$31.6MOct 2014
    Aileron Therapeutics logoAileron TherapeuticsUnknown$12MJan 2013
    CCerecorSeries A$6.8MApr 2012
    Aileron Therapeutics logoAileron TherapeuticsSeries D$40MJun 2009
    Tendyne logoTendyneSeries C$25M—
    Tokai Pharmaceuticals logoTokai PharmaceuticalsSeries E$35.5M—
    VVytronUSSeries C$49M—

    Top Co-Investors

    Sofinnova Partners4 shared
    Cormorant Asset Management3 shared
    Versant Ventures3 shared
    Scale Venture Partners2 shared
    Fidelity Investments2 shared
    Gilmartin Capital2 shared
    Intuitive Ventures2 shared
    Redmile Group2 shared
    Venrock2 shared
    Roche Venture Fund2 shared
    AJU IB Investment2 shared
    SR One2 shared
    Mass General Brigham Ventures2 shared
    New Enterprise Associates2 shared
    Windham Capital Partners2 shared
    T. Rowe Price1 shared
    Perceptive Xontogeny Venture Fund1 shared
    Ally Bridge Group1 shared
    Norwest Venture Partners1 shared
    venBio1 shared

    Last updated: 8 September 2026